JP2011530607A5 - - Google Patents

Download PDF

Info

Publication number
JP2011530607A5
JP2011530607A5 JP2011523078A JP2011523078A JP2011530607A5 JP 2011530607 A5 JP2011530607 A5 JP 2011530607A5 JP 2011523078 A JP2011523078 A JP 2011523078A JP 2011523078 A JP2011523078 A JP 2011523078A JP 2011530607 A5 JP2011530607 A5 JP 2011530607A5
Authority
JP
Japan
Prior art keywords
lower alkyl
phenyl
substituted
amino
pyrimidylaminobenzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011523078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011530607A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/053358 external-priority patent/WO2010019540A1/en
Publication of JP2011530607A publication Critical patent/JP2011530607A/ja
Publication of JP2011530607A5 publication Critical patent/JP2011530607A5/ja
Pending legal-status Critical Current

Links

JP2011523078A 2008-08-13 2009-08-11 肺動脈高血圧の治療 Pending JP2011530607A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8838208P 2008-08-13 2008-08-13
US61/088,382 2008-08-13
US16450109P 2009-03-30 2009-03-30
US61/164,501 2009-03-30
PCT/US2009/053358 WO2010019540A1 (en) 2008-08-13 2009-08-11 Treatment of pulmonary arterial hypertension

Publications (2)

Publication Number Publication Date
JP2011530607A JP2011530607A (ja) 2011-12-22
JP2011530607A5 true JP2011530607A5 (enExample) 2012-09-27

Family

ID=41137217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011523078A Pending JP2011530607A (ja) 2008-08-13 2009-08-11 肺動脈高血圧の治療

Country Status (16)

Country Link
US (1) US20110190313A1 (enExample)
EP (1) EP2315592A1 (enExample)
JP (1) JP2011530607A (enExample)
KR (1) KR20110053354A (enExample)
CN (1) CN102123711A (enExample)
AU (1) AU2009282104A1 (enExample)
BR (1) BRPI0917491A2 (enExample)
CA (1) CA2732789A1 (enExample)
CL (1) CL2011000295A1 (enExample)
IL (1) IL210922A0 (enExample)
MA (1) MA32617B1 (enExample)
MX (1) MX2011001668A (enExample)
NZ (1) NZ590839A (enExample)
RU (1) RU2011109078A (enExample)
TW (1) TW201010999A (enExample)
WO (1) WO2010019540A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
WO2014110200A1 (en) 2013-01-10 2014-07-17 Zisman Lawrence S Non-selective kinase inhibitors
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
MX389551B (es) 2016-10-27 2025-03-20 Pulmokine Inc Politerapia para tratar hipertension pulmonar.
CA3042123A1 (en) 2016-11-08 2018-05-17 Reata Pharmaceuticals, Inc. Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
US20210038510A1 (en) * 2018-02-08 2021-02-11 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
WO2020232238A1 (en) 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Inhalable formulations for kinase inhibition
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US20210154193A1 (en) * 2019-11-25 2021-05-27 PHPrecisionMed, LLC Pharmaceutical compositions for the treatment of pulmonary hypertension
AU2021339756A1 (en) * 2020-09-11 2023-04-13 Pulmosim Therapeutics Llc Compositions and methods for treating or preventing pulmonary hypertension
CA3199324A1 (en) 2020-11-17 2022-05-27 Adam Marc Silverstein Inhaled imatinib for pulmonary hypertension field

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003272007A1 (en) * 2002-10-25 2004-05-13 The Administrators Of The Tulane Educational Fund Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
US20080114001A1 (en) * 2005-01-28 2008-05-15 Manley Paul W Use of Pyrimidylaminobenzamides for the Treatment of Diseases that Respond to Modulation of Tie-2 Kinase Activity
ES2593319T3 (es) * 2005-05-02 2016-12-07 Novartis Ag Derivados de pirimidilaminobenzamida para síndrome hipereosinofílico
BRPI0619416A2 (pt) * 2005-12-06 2011-10-04 Novartis Ag derivados de pirimidilaminobenzamida para o tratamento da neurofibromatose
CN101622244A (zh) * 2006-11-03 2010-01-06 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物

Similar Documents

Publication Publication Date Title
JP2011530607A5 (enExample)
USRE49556E1 (en) Compounds and compositions as protein kinase inhibitors
US10774065B2 (en) 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
US9815813B2 (en) 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
AU2015207757B2 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
RU2011109078A (ru) Лечение легочной артериальной гипертензии
RU2011137399A (ru) Гетероциклическое производное
RU2012147511A (ru) Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза
RS57177B1 (sr) Derivati benzamida za inhibiranje aktivnosti abl1, abl2 i bcr-abl1
RU2012124811A (ru) СПОСОБ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И ДРУГИХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ АКТИВНОСТЬЮ КИНАЗ Bcr-Abl, c-Kit, DDR1, DDR2, ИЛИ PDGF-R
JP2009532438A5 (enExample)
RU2012120901A (ru) Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r
RU2011105059A (ru) Применение производных пиримидиламинобензамида для лечения фиброза
JP2009537606A5 (enExample)
CN113543784A (zh) 用于治疗或预防癌症的喹啉衍生物
EP2437745A1 (en) Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms
JP2019530711A5 (enExample)
RU2008127264A (ru) Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
RU2007132255A (ru) Применение пиримидиламинобензамидов для лечения заболеваний, чувствительных к модуляции активности киназы tie-2
JP2012519668A5 (enExample)
US20110281813A1 (en) Method of treating c-kit positive relapsed acute myeloid leukemia
RU2007147957A (ru) Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
JP2009501765A5 (enExample)
RU2007135284A (ru) Фармацевтические комбинации ингибиторов киназ bcr-abl и raf
US20100298338A1 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit